Collagen Binding Assay for von Willebrand Factor (VWF:CBA): Detection of von Willebrands Disease (VWD), and Discrimination of VWD Subtypes, Depends on Collagen Source

Summary

A large number of different collagen preparations [n = 21] have been assessed for their ability to both detect von Willebrands Disease (VWD), and discriminate different VWD subtypes. Collagen preparations were tested at a range of concentrations and included: Type I, III and IV, and various mixtures of these, as aqueous supplied preparations and/or reconstituted from bulk lyophilised stock. Tissue sources for collagens ranged from human placenta to calf skin to equine tendon. Three of the collagen preparations tested did not support von Willebrand factor (VWF) binding in an ELISA process (therefore unable to detect VWD). The ability of the remaining preparations to detect VWF was variable, as was their ability to discriminate VWD subtypes. Detection of VWF and discrimination of VWD subtypes was not mutually inclusive. Thus, some collagen preparations provided excellent detection systems for VWF, but comparatively poorer discrimination of Type 2 VWD, while others provided good to acceptable detection and discrimination. Subtype discrimination was also dependent on the collagen concentration, and some batch to batch variation was evident with some preparations (particularly Type I collagens). Overall, best discrimination was typically achieved with Type I/III collagen mixtures, or Type III collagen preparations (where effectiveness was highly dependent on concentration). Good discrimination was also achieved with a commercial Type III collagen based VWF:CBA kit method. Results of the various ‘VWF:CBA assays’ are also compared with those using the Ristocetin Cofactor (VWF:RCof) assay (by platelet agglutination) and that using a commercial ‘VWF:RCof-alternative/ activity’ ELISA procedure. These latter methodologies tended to be less sensitive to VWF-discordance when compared to that detected by the majority of the VWF:CBA procedures.

Abbreviations: FVIII:C Factor VIII: coagulant (assay); HMW High Molecular Weight [VWF]; PNP Pooled Normal Plasma; RIPA Ristocetin induced platelet aggregation procedure; VWD von Willebrands disease; VWF von Willebrand Factor; VWF:Ag von Willebrand Factor Antigen (assay); VWF: CBA Collagen Binding [Activity] Assay for VWF; VWF:RCof Ristocetin Cofactor Assay for VWF

Keywords

von Willebrand factor - VWF - von Willebrands disease - VWD - collagen binding assay - collagen - VWF:CBA

• References

• 1 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s Disease. Blood 1987; 69: 454-9.
• 2 Sadler JE, Gralnick HR. Commentary: A new classification for von Willebrand Disease. Blood 1994; 84: 676-9.
• 3 Sadler JE. Review: Von Willebrand Factor. J Biol Chem 1991; 266: 22777-80.
• 4 Moroose R, Hoyer LW. von Willebrand factor and platelet function. Ann Rev Med 1986; 37: 157-63.
• 5 Giddings JC, Peake IR. The investigation of factor VIII deficiency. In: Thompson JM. ed. Blood Coagulation and Haemostasis. New York: Churchill Livingstone; 1985: 135-207.
• 6 Girma J-P, Meyer D, Verweij CL. et al. Structure-function relationship of human von Willebrand factor. Blood 1987; 70: 605-11.
• 7 Sadler JE. A revised classification of von Willebrand Disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-5.
• 8 Guidelines for the diagnosis and management of von Willebrand Disease. Prepared by the Von Willebrand Working Party of the United Kingdom Haemophilia Centre Directors’ Organisation. 1995
• 9 Sadler JE, Foster PA, George JN. Haemostasis/Platelets. In: Haematology. 1996 ed McArthur JR. The Education Program of the American Society of Hematology; 1996: 79-94.
• 10 Favaloro EJ, Koutts J. Laboratory assays for von Willebrand Factor: Relative contribution to the diagnosis of von Willebrand’s disease. Pathology 1997; 29: 385-391.
• 11 Brown RA, Rodgers GM. von Willebrand’s Disease. Check Sample. Clinical Haematology No. CH 96-4 (CH-14). American Society of Clinical Pathologists; 1996: 45-62.
• 12 Fleming TGM. von Willebrand factor: its function and its measurement in the laboratory. Br J Biomed Sci 1995; 52: 50-7.
• 13 Favaloro EJ, Smith J, Petinos P, Hertzberg H, Koutts J. on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel. Laboratory testing for von Willebrand’s disease: An assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost 1999; 82: 1276-82.
• 14 Favaloro EJ, Smith J, Petinos P, Collecutt M, Street A, Hertzberg M. On behalf of the RCPA Quality Assurance Program (QAP) in Haematology Scientific Haemostasis Advisory Panel (1999). Laboratory testing, diagnosis and management of von Willebrand’s disease: Current practice in Australasia. Am J Clin Pathol 1999; 112: 712-9.
• 15 Howard MA, Firkin BG. Ristocetin. A new tool in the investigation of platelet aggregation. Throm Diath Haemorrh 1971; 26: 362-5.
• 16 Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand’s Disease that is necessary for platelet aggregation. J Clin Invest 1973; 52: 2708-17.
• 17 MacFarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand’s factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-8.
• 18 Favaloro EJ, Mehrabani PA, Koutts J. Laboratory assessment of von Willebrand factor: altered interpretation of laboratory data, and altered diagnosis of von Willebrand’s disease, as influenced by the use of different vWF assays and assay conditions. Clin Appl Thromb/Hemost 1997; 03: 110-8.
• 19 Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II, von Willebrand’s disease. Blood Coagul and Fibrinolysis 1991; 02: 285-91.
• 20 Favaloro EJ, Grispo L, Dinale A, Berndt M, Koutts J. von Willebrand’s Disease: Laboratory investigation using an improved functional assay for von Willebrand factor. Pathology 1993; 25: 152-8.
• 21 Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
• 22 Favaloro EJ, Facey D, Grispo L. Laboratory assessment of von Willebrand factor: Use of different assays can influence the diagnosis of von Willebrand’s disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms. Am J Clin Pathol 1995; 104: 264-71.
• 23 Favaloro EJ, Dean M, Grispo L, Exner T, Koutts J. von Willebrand’s Disease: Use of Collagen Binding Assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy. Am J Hematol 1994; 45: 205-11.
• 24 Ramasamy I, Farrugia A, Tran E, Anastasius V, Charnock A. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay. Biologicals 1998; 26: 155-66.
• 25 Fischer BE, Kramer G, Mitterer A, Grillberger L, Reiter M, Mundt W, Dorner F, Eibl J. Effect of multimerisation of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res 1996; 84: 55-66.
• 26 Fischer BE, Thomas KB, Dorner F. von Willebrand factor: measuring its antigen or function? Correlation between the level of antigen, activity, and multimer size using various detection systems. Thromb Res 1998; 91: 39-43.
• 27 Casonato A, Pontara E, Bertomoro A, Zucchetto S, Zerbinati P, Girlami A. Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers. J Lab Clin Med 1997; 129: 251-9.
• 28 Kempfer AC, Silaf MR, Farias CE, Carballo GA, Woods AI, Lazzari MA. Binding of von Willebrand Factor to Collagen by Flow Cytometry. Am J Clin Pathol 1999; 111: 418-23.
• 29 Facey DA, Favaloro EJ, Koutts J, Berndt MC, Hertzberg M. Identification and characterisation of a novel mutation in von Willebrand Factor causing a Type 2B von Willebrand’s Disease. Br J Haematol 1999; 105: 538-41.
• 30 Siekmann J, Turecek PL, Fischer BE, Mitterer A, Schlokat U, Falkner F, Dorner F, Schwarz HP. Characterisation of plasma-derived and recombinant human VWF by improved collagen binding assays. Thromb Haemost 1995; 73: 1160.
• 31 Fischer BE, Thomas KB, Dorner F. Collagen covalently immobilised onto plastic surfaces simplifies measurment of von Willebrand factor-collagen binding activity. Ann Hematol 1998; 76: 159-66.
• 32 Siekmann J, Turecek PL, Schwarz HP. The determination of von Willebrand factor activity by collagen binding assay. Hemophilia 1998; 4 Suppl 3: 15-24.
• 33 van Zanten GH, Saelman EUM, Schut-Hese KM, Wu YP, Slootweg PJ, Niewenhuis HK, de Groot PG, Sixma JJ. Platelet adhesion to Collagen Type IV under flow conditions. Blood 1996; 88: 3862-71.
• 34 Preston FE. Assays for von Willebrand Factor Functional Activity: A UK NEQAS Survey. Thromb Haemost 1998; 80: 863.
• 35 Goodall AH, Jarvis J, Chand S, Rawlings E, O’Brien DP, McCraw A, Hutton R, Tuddenham EGD. An immunoradiometric assay for human factor VIII von Willebrand factor (VIII:VWF) using a monoclonal antibody based that defines a functional epitope. Br J Haematol 1985; 59: 565-77.
• 36 Chand S, McCraw A, Hutton R, Tuddenham EGD, Goodall AH. A two-site, monoclonal antibody based immunoassay for von Willebrand factor- Demonstration that VWF function resides in a conformational epitope. Thromb Haemost 1986; 55: 318-24.
• 37 Murdock PJ, Woodhams BJ, Mathews KB, Pasi KJ, Goodall AH. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the Ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 1272-7.